An accessible patient-derived xenograft model of low-risk myelodysplastic syndromes.
暂无分享,去创建一个
L. Gondek | Patric Teodorescu | A. DeZern | G. Ghiaur | I. Choi | W. Dalton | Sergiu-Vlad Paşca | Cynthia Shams
[1] W. Liu,et al. The Coming of Age of Preclinical Models of MDS , 2022, Frontiers in Oncology.
[2] J. Abkowitz,et al. Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome , 2021, Blood.
[3] Xiaomei Ma,et al. Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. , 2019, Blood reviews.
[4] Y. Kluger,et al. A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies , 2018, Nature Communications.
[5] B. Ebert,et al. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia , 2016, Nature Reviews Cancer.
[6] A. Trumpp,et al. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. , 2014, Cell stem cell.
[7] A. Palucka,et al. Development and function of human innate immune cells in a humanized mouse model , 2014, Nature Biotechnology.
[8] M. Kotb,et al. Human Lymphoid and Myeloid Cell Development in NOD/LtSz-scid IL2Rγnull Mice Engrafted with Mobilized Human Hemopoietic Stem Cells 12 , 2004, The Journal of Immunology.
[9] Y. Nagata. [Molecular international prognostic scoring system for myelodysplastic syndromes]. , 2023, [Rinsho ketsueki] The Japanese journal of clinical hematology.